

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

NEPTUNE GENERICS, LLC,  
APOTEX INC., APOTEX CORP., TEVA PHARMACEUTICALS,  
FRESENIUS KABI USA, LLC, and  
WOCKHARDT BIO AG  
Petitioners,

v.

ELI LILLY & COMPANY,  
Patent Owner.

---

Case No. IPR2016-00237<sup>1</sup>  
Patent No. 7,772,209

---

**PATENT OWNER ELI LILLY AND COMPANY'S  
OPPOSITION TO MOTION TO EXCLUDE EVIDENCE**

---

<sup>1</sup> Cases IPR2016-01190, IPR2016-01335, and IPR2016-01341 have been joined with the instant proceeding.

**TABLE OF CONTENTS**

I. DR. CHABNER’S TESTIMONY SHOULD NOT BE EXCLUDED .....1

    A. Dr. Chabner’s Application of Legal Standards Does Not  
        Warrant Exclusion of His Testimony.....2

    B. Dr. Chabner’s Disagreement with Post-Priority Date  
        Characterizations of the Prior Art Do Not Warrant Exclusion.....6

II. DR. NIYIKIZA’S TRIAL TESTIMONY SHOULD NOT BE  
EXCLUDED.....9

**TABLE OF AUTHORITIES**

**CASES**

*Arceo v. City of Junction City*, 182 F. Supp.2d 1062 (D. Kan. 2002) ..... 13

*Eli Lilly & Co. v. Teva Parenteral Medicines, et al.*, Case No. 1:10-cv-1376-TWP-DKL (S.D. Ind.) ..... 1, 14

*Kinetic Concepts, Inc. v. Smith & Nephew, Inc.*, 688 F.3d 1342 (Fed. Cir. 2012) ..... 8

*LG Chem, Ltd. v. Celgard, LLC*, IPR2014-00692, Paper 76 (PTAB Oct. 5, 2015) ..... 4

*Lupin Ltd. v. Senju Pharm. Co., Ltd.*, IPR2015-01099, Paper 69 (PTAB Sept. 12, 2016) ..... 3, 5, 6, 9

*Nutrition 21 v. United States*, 930 F.2d 867 (Fed. Cir. 1991) ..... 4

*Petroleum Geo-Services, Inc. v. WesternGeco, LLC*, IPR2014-01477, Paper 71 (PTAB July 11, 2016) ..... 11, 13

*SK Innovation Co. v. Celgard, LLC*, IPR2014-00680, Paper 57 (PTAB Sept. 25, 2015) ..... 4

*United States v. Inadi*, 475 U.S. 387 (1986) ..... 13

*Valeo N.A., Inc., et al. v. Magna Elecs., Inc.*, IPR2014-00220, Paper 59 (PTAB May 28, 2015) ..... 6

**OTHER AUTHORITIES**

37 C.F.R. § 42.51 ..... 10, 11

37 C.F.R. § 42.53 ..... 10, 11

37 C.F.R. § 42.64 ..... 6, 15

Federal Rule of Evidence 702 ..... 3, 9

Federal Rule of Evidence 801 ..... 6

Federal Rule of Evidence 804.....14  
McCormick on Evidence § 301 .....13

Patent Owner Eli Lilly and Company (“Lilly”) respectfully submits this Opposition to the Motion to Exclude (Paper 57, “Mot.”) filed by Petitioner Neptune Generics, LLC (“Neptune”). Neptune’s motion is a transparent attempt to garner additional pages within which to make merits arguments. Nothing it argues justifies the exclusion of evidence, and its motion should be denied.

**I. DR. CHABNER’S TESTIMONY SHOULD NOT BE EXCLUDED**

Neptune seeks to exclude in its entirety the declaration of Dr. Bruce Chabner (Ex. 2120), Lilly’s principal expert witness, on the grounds that his testimony is “unreliable.” Mot. at 1-7. Dr. Chabner is the former Clinical Director of the Massachusetts General Hospital Cancer Center, former Director of the Division of Cancer Treatment at the National Cancer Institute at NIH, a Professor of Medicine at Harvard Medical School, and a recognized expert in antifolates. Ex. 2120 ¶¶ 1, 10-20. During a two-week bench trial against Joinder-Petitioners Teva and Fresenius, Dr. Chabner expressed substantially the same opinions about the same issues about the same patent as are at issue here. Far from finding this testimony so “unreliable” that it should be excluded wholesale, the district court expressly relied on this testimony, and, moreover, expressly found Dr. Chabner to be “more credible with respect to [his] opinions on how a POSA would view the teachings of Worzalla and Hammond than Defendants’ experts.” *Eli Lilly & Co. v. Teva Parenteral Medicines, et al.*, Case No. 1:10-cv-1376-TWP-DKL, ECF No. 336 at

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.